FDA slaps enrollment hold on 2 Tecentriq studies after Keytruda myeloma trial deaths
admin 18th September 2017 Uncategorised 0Keytruda’s stumble in multiple myeloma has hit another of its peers. Roche said Friday that, because of deaths in Keytruda’s combo trials with Celgene meds, the FDA put a partial hold on certain Tecentriq studies so it can assess the situation.
More: FDA slaps enrollment hold on 2 Tecentriq studies after Keytruda myeloma trial deaths
Source: fierce